PCP
PCVX icon

Perbak Capital Partners’s Vaxcyte PCVX Stock Holding History

Perbak Capital Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,899
Closed -$411K – 365
2025
Q4 		$411K Sell
8,899
-32,032
-78% -$1.43M 0.13% 91
2025
Q3 		$1.47M Buy
40,931
+14,512
+55% +$481K 0.26% 29
2025
Q2 		$859K Buy
+26,419
New +$866K 0.19% 60

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perbak Capital Partners's PCVX Position: Q1 2026 in Review

Perbak Capital Partners sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 8,899 shares — an estimated $411K sold.

Perbak Capital Partners first reported a position in PCVX in Q2 2025 and held it in 3 quarters. The position peaked at $1.47M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Perbak Capital Partners reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 8,899 Vaxcyte shares in Q1 2026, an estimated $411K.
  • Perbak Capital Partners first reported a position in Vaxcyte in Q2 2025 and held it in 3 quarters.
  • Perbak Capital Partners's Vaxcyte position peaked at $1.47M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.